Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
32 studies found for:    "Chordoma"
Show Display Options
Rank Status Study
21 Recruiting A Study of IMRT in Primary Bone and Soft Tissue Sarcoma
Conditions: Soft Tissue Sarcoma,;   Ewing Sarcoma;   Bone Sarcoma;   Chordoma
Intervention: Radiation: Intensity modulated radiotherapy (IMRT)
22 Completed Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
Conditions: Childhood Alveolar Soft-part Sarcoma;   Childhood Angiosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Childhood Epithelioid Sarcoma;   Childhood Fibrosarcoma;   Childhood Leiomyosarcoma;   Childhood Liposarcoma;   Childhood Malignant Mesenchymoma;   Childhood Neurofibrosarcoma;   Childhood Synovial Sarcoma;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Soft Tissue Sarcoma
Intervention: Other: laboratory biomarker analysis
23 Active, not recruiting Stereotactic Body Radiotherapy for Spine Tumors
Conditions: Spinal Metastases;   Vertebral Metastases;   Benign Spinal Tumors;   Chordoma;   Meningioma;   Schwannoma;   Neurofibroma;   Paragangliomas;   Arteriovenous Malformations
Intervention: Radiation: stereotactic body radiotherapy
24 Recruiting Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
25 Recruiting HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Conditions: Rhabdomyosarcoma;   Osteosarcoma;   Ewing Sarcoma;   Soft Tissue Sarcoma;   Neuroblastoma;   Wilms Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Clival Chordoma;   Non-CNS Solid Tumors
Intervention: Biological: HSV1716
26 Active, not recruiting Stereotactic Body Radiotherapy for Head and Neck Tumors
Conditions: Squamous Cell Carcinoma of the Head and Neck;   Nasopharyngeal Carcinoma;   Salivary Gland Cancer;   Head and Neck Sarcoma;   Paraganglioma of Head and Neck;   Chordoma of Head and Neck;   Chondrosarcoma of Head and Neck;   Angiofibroma of Head and Neck
Interventions: Radiation: stereotactic body radiotherapy;   Radiation: Stereotactic body radiotherapy
27 Not yet recruiting Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors
Condition: Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Interventions: Radiation: Carbon ions therapy;   Radiation: Advanced external radiotherapy by Xrays or protons
28 Active, not recruiting Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
Condition: Brain Tumor, Recurrent
Intervention: Drug: Photofrin photodynamic therapy.
29 Recruiting Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
Condition: Solid Tumor Malignancies
Intervention: Biological: Clostridium novyi-NT spores
30 Active, not recruiting Photodynamic Therapy (PDT) for Brain Tumors
Condition: Brain Tumor, Recurrent
Intervention: Drug: Photofrin (porfimer sodium) & photodynamic therapy.
31 Completed Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate
Condition: Cancer
Interventions: Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 );   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2);   Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3);   Procedure: Blood sampling
32 Completed Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Condition: Life Threatening Diseases
Intervention: Drug: Imatinib mesylate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-32) Next Page   
Indicates status has not been verified in more than two years